Peer-reviewed veterinary case report
Cerebrospinal fluid markers and magnetic resonance imaging lesion volume predicting relapse in canine meningoencephalitis of unknown origin.
- Journal:
- Frontiers in veterinary science
- Year:
- 2026
- Authors:
- Spohn, Franziska et al.
- Affiliation:
- Department of Small Animal Medicine and Surgery · Germany
- Species:
- dog
Plain-English summary
This study looked at 35 dogs diagnosed with meningoencephalitis of unknown origin (MUO), a serious brain condition that can come back after treatment. The researchers wanted to find out if certain tests, like checking the cerebrospinal fluid (the fluid around the brain and spine) or doing MRI scans, could help predict if a dog would have a relapse. They found that higher levels of albumin (a protein) and lymphocytes (a type of white blood cell) in the cerebrospinal fluid during follow-up exams were linked to a higher chance of relapse. While MRI scans showed changes in the brain after treatment, they weren't very reliable for predicting future relapses. Overall, the study concluded that monitoring these specific cerebrospinal fluid markers could help identify dogs at risk for relapse after treatment.
Abstract
INTRODUCTION: Meningoencephalitis of unknown origin (MUO) is a potentially lethal neurological disease in dogs with a high relapse rate. Prognostic factors for relapse based on neurological examination, magnetic resonance imaging (MRI), or cerebrospinal fluid (CSF) examination are inconsistently reported. METHODS: This retrospective single center study included 35 dogs with MUO. Brain MRI, CSF findings, clinical signs at diagnosis and during follow-up MRI (routine or relapse-related) were analyzed. Lesion volumes were calculated using the Cavalieri method. Relapse predictors were evaluated for routine follow- up MRI examinations using logistic regression and ROC/AUC. RESULT: Only higher CSF albumin (= 0.0413) and lymphocyte proportion (= 0.0288) at routine follow-up examination were predictive of future relapse. ROC analyses identified thresholds of 9.64 mg/dl for CSF albumin (AUC: 0.75; sensitivity 86.7%, specificity 61.1%) and 74.0% for CSF lymphocytes (AUC 0.76; sensitivity 66.7%, specificity 64.3%). Total lesion volume and volume of contrast-enhancing lesions decreased after treatment and increased again at relapse. Increased lesion volume or normal MRI on routine follow-up MRI did not reliably predict future relapse, although increased lesion volume in T1-weighted contrast enhancement and Fluid-attenuated inversion recovery (FLAIR) was observed at or after relapse. Lesion volume, lesion number, and lesion localization in different sequences was associated with neurodisability scale (NDS) and epileptic seizures. DISCUSSION: In this study, CSF albumin and lymphocyte proportion were identified as predictors of future relapse. Routine follow-up MRI was not predictive of future relapse, but useful for detection of an active inflammation.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://pubmed.ncbi.nlm.nih.gov/41743563/